Special Sources of Funds
Cooperative Research and Development Agreements (CRADAs)
Under the Federal Technology Transfer Act of 1986 (PL 99-502), government laboratories are authorized to enter into Cooperative Research and Development Agreements (CRADAs) with private sector entities. Licensing agreements are usually incorporated into the CRADA document that address patent rights attributable to research supported under the CRADA.
|Fiscal Year||Carryover from Prior Year||Collections||Obligations|
NCI retains a portion of the royalty income generated by the patents related to NCI-funded research. A major portion of this royalty income is used to support employees of the laboratory, further scientific exchange, and provide education and training based on the terms of the Federal Technology Transfer Act (PL 99-502). Royalty income is also used to support costs associated with processing and collecting royalty income and for technology transfer efforts at NCI and NIH.
|*Does not include assessments by NIH.|
|**2015/2017 and 2016/2018 payments are estimates.|
Stamp Out Breast Cancer Act
The Stamp Out Breast Cancer Act (PL 105-41) was established in August 1997, extended in July 2000 (PL 106-253), November 2005 (PL 109-100), December 2007 (PL 110-150), December 2011 (PL 112-80), and in December 2015 (PL 114-99). This act allows postal customers to contribute funding to breast cancer research through their voluntary purchases of special rate postage stamps from the U.S. Postal Service (USPS). Of the funds collected above the postage costs and administrative costs, the Act requires the USPS to transfer 70% to NIH and 30% to the Department of Defense. As of September 2016, NCI has received $58,035,139. NCI has used these funds for research projects directed towards breast cancer research. Thus far, five major programs have been funded, including the Insight Awards to Stamp Out Breast Cancer, the Breast Cancer Research Stamp Exception Program, the Breast Cancer Premalignancy Program, a clinical trial to determine the risk of breast cancer recurrence, and the Molecular and Cellular Characterization of Screen Detected Lesions Consortium. In FY 2016, $1,654,151 million was obligated on Breast Cancer Stamp Fund programs.